A Phase 2 interventional study of Lebrikizumab and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 112 sites in 13 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-24.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 2, and was the 7th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 505 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 27 finished, 15 (56%) have results posted.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2013, is one of 9 in phase 2, and was the 13th registered.
Hoffmann-La Roche’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2000.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 29 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.
Inclusion Criteria:
Exclusion Criteria:
Exclusions Criteria Limited to Cohort B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
Drug: Lebrikizumab · Drug: Placebo
Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
Drug: Lebrikizumab
Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
Drug: Pirfenidone · Drug: Placebo
Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
Drug: Lebrikizumab · Drug: Pirfenidone
Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
Also known as: RO5490255
Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks
Annualized rates of decrease (slope throughout time from baseline to Week 52) for percent predicted FVC was assessed and reported. FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks
Annualized rates of decline (slope throughout time from baseline to Week 52) in 6MWT was assessed and reported. 6MWT was the distance (in meters \[m\]) that a participant could walk in 6 minutes.
Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Percentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
Time frame: Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)
Time to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100. Time from randomization to first occurrence of an event of \>/=10% absolute decline in percent predicted FVC or death from any cause was reported. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median time to event was estimated using Kaplan-Meier method. 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)
Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks
Annualized rates of decrease (slope throughout time from baseline to Week 52) in DLco was assessed and reported. DLco (in milliliters per minute/millimeters of mercury \[mL/min/mmHg\]) is a measure of the gas transfer.
Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Percentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100.
Time frame: Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)
Progression-Free Survival (PFS)
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100. PFS was defined as time from randomization to death from any cause, all cause hospitalization, or a decrease from baseline of \>/=10% in FVC, whichever occurred first. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median PFS was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)
Annualized Rate of Decrease in FVC Over 52 Weeks
Annualized rates of decrease (slope throughout time from baseline to Week 52) in FVC (in milliliters per year \[mL/year\]) was assessed and reported. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position.
Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks
The ATAQ-IPF Version 3 was utilized that included 31 items within 5 domains: cough (6 items), dyspnea (7 items), exhaustion (6 items), emotional well-being (6 items), and independence (6 items). Each item was assessed on a scale ranging from 1 (Strongly disagree) to 4 (Strongly agree). The ATAQ-IPF had a recall specification of 2 weeks. Simple summation scoring was used to derive individual domain scores as well as a total score. ATAQ-IPF total score ranged from 31 to 124 with lower score indicating better quality of life (QoL). Annualized rates of decrease (slope throughout time from baseline to Week 52) in ATAQ-IPF questionnaire total score was assessed and reported.
Time frame: Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Percentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause
The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Percentage of participants with an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported.
Time frame: Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)
Time to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause
The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Time from randomization to first occurrence of an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)
Percentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, such as left heart failure, pulmonary embolism, pulmonary infection (on the basis of endotracheal aspirate or bronchoalveolar lavage if available, or investigator judgment), or other events leading to acute lung injury (for example, sepsis, aspiration, trauma, reperfusion pulmonary edema).
Time frame: Baseline up to the event of acute IPF exacerbation (up to Week 122)
Time to First Event of Acute IPF Exacerbation
Time from randomization to first occurrence of an event of IPF exacerbation was reported. IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, or other events leading to acute lung injury. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to the event of acute IPF exacerbation (up to Week 122)
Percentage of Participants With Respiratory-Related Hospitalization
Time frame: Baseline up to the event of respiratory-related hospitalization (up to Week 122)
Time to Respiratory-Related Hospitalization
Time from randomization to first occurrence of an event of respiratory-related hospitalization was reported. Participants without an event were censored at the last known alive day, study Day 368, or the last date during the double-blind period. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to the event of respiratory-related hospitalization (up to Week 122)
Percentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause
DLco (in mL/min/mmHg) is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100.
Time frame: Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)
Time to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause
DLco is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100. Time from randomization to first occurrence of \>/=15% absolute decrease in percentage of predicted DLco or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)
Percentage of Participants With Anti-therapeutic Antibody (ATA) to Lebrikizumab
ATA to lebrikizumab was tested using a validated immunoassay. A positive ATA result was defined as one in which the presence of detectable ATAs could be confirmed by competitive binding with lebrikizumab. Percentage of participants with positive results for ATA at Baseline and at post-baseline time points were reported. Only participants who received lebrikizumab were included in the analysis.
Time frame: Baseline and Post-Baseline (assessed at multiple time points: Weeks 4, 12, 24, 36, 52, 56, 64, 76, and at safety follow-up up to Week 122)
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 52
Participants who received lebrikizumab were only included in the analysis.
Time frame: Predose (Hour 0) at Week 52
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab
Participants who received lebrikizumab were only included in the analysis.
Time frame: Predose (Hour 0) at Weeks 4, 12, 24, and 36
Elimination Half-Life (t1/2) of Lebrikizumab
Elimination half-life is the time measured for the plasma drug concentration to decrease by one-half during the elimination phase of the drug. Analysis was performed on PK-Evaluable Population. Participants who received lebrikizumab were only included in the analysis.
Time frame: Pre-dose (Hour 0) at Weeks 1, 4, 12, 24, 36, 64, 76, 88, 104; and at 4, 12, and 18 weeks post-last dose (last dose = Week 104)
| Milestone | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Started | 76 | 78 | 177 | 174 |
| Completed | 56 | 58 | 129 | 136 |
| Not completed | 20 | 20 | 48 | 38 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 6 | 3 |
| Withdrew: Withdrawal by subject | 9 | 8 | 14 | 16 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 3 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
| Withdrew: Death | 3 | 4 | 14 | 9 |
| Withdrew: Adverse event | 6 | 3 | 10 | 7 |
| Milestone | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Started | 52 | 56 | 0 | 0 |
| Completed | 31 | 33 | 0 | 0 |
| Not completed | 21 | 23 | 0 | 0 |
| Withdrew: Other | 2 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 12 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 | 0 |
| Withdrew: Death | 5 | 3 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 |
Annualized rates of decrease (slope throughout time from baseline to Week 52) for percent predicted FVC was assessed and reported. FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
| percent predicted FVC/year | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks | -6.1876 ± 0.92597 | -5.2065 ± 0.92758 | -6.0430 ± 0.60633 | -5.5430 ± 0.59507 |
Annualized rates of decline (slope throughout time from baseline to Week 52) in 6MWT was assessed and reported. 6MWT was the distance (in meters \[m\]) that a participant could walk in 6 minutes.
| m/year | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks | -44.6512 ± 15.97862 | -22.7209 ± 15.34753 | -25.5683 ± 12.24923 | -46.9810 ± 11.84199 |
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
| percentage of participants | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Percentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause | 34.2 | 27.6 | 30.3 | 26.6 |
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100. Time from randomization to first occurrence of an event of \>/=10% absolute decline in percent predicted FVC or death from any cause was reported. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median time to event was estimated using Kaplan-Meier method. 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
| weeks | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Time to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause | 53.1 (52.6 to NA) | NA (NA to NA) | NA (52.9 to NA) | NA (NA to NA) |
Annualized rates of decrease (slope throughout time from baseline to Week 52) in DLco was assessed and reported. DLco (in milliliters per minute/millimeters of mercury \[mL/min/mmHg\]) is a measure of the gas transfer.
| mL/min/mmHg/year | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks | -4.7818 ± 0.74479 | -4.2400 ± 0.73826 | -5.7552 ± 0.46561 | -5.5732 ± 0.45577 |
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100.
| percentage of participants | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Percentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC | 47.4 | 32.9 | 39.4 | 39.9 |
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100. PFS was defined as time from randomization to death from any cause, all cause hospitalization, or a decrease from baseline of \>/=10% in FVC, whichever occurred first. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median PFS was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| weeks | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Progression-Free Survival (PFS) | 52.6 (43.9 to NA) | NA (NA to NA) | NA (NA to NA) | NA (52.3 to NA) |
Annualized rates of decrease (slope throughout time from baseline to Week 52) in FVC (in milliliters per year \[mL/year\]) was assessed and reported. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position.
| mL/year | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Annualized Rate of Decrease in FVC Over 52 Weeks | -221.029 ± 34.87511 | -192.906 ± 34.93853 | -231.167 ± 22.67786 | -209.437 ± 22.25073 |
The ATAQ-IPF Version 3 was utilized that included 31 items within 5 domains: cough (6 items), dyspnea (7 items), exhaustion (6 items), emotional well-being (6 items), and independence (6 items). Each item was assessed on a scale ranging from 1 (Strongly disagree) to 4 (Strongly agree). The ATAQ-IPF had a recall specification of 2 weeks. Simple summation scoring was used to derive individual domain scores as well as a total score. ATAQ-IPF total score ranged from 31 to 124 with lower score indicating better quality of life (QoL). Annualized rates of decrease (slope throughout time from baseline to Week 52) in ATAQ-IPF questionnaire total score was assessed and reported.
| units on a scale/year | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks | 6.8907 ± 1.71778 | 4.7886 ± 1.70370 | 5.6189 ± 0.99880 | 5.4558 ± 0.97793 |
The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Percentage of participants with an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported.
| percentage of participants | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab |
|---|---|---|
| Percentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause | 57.9 | 48.7 |
The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Time from randomization to first occurrence of an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| weeks | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab |
|---|---|---|
| Time to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause | 51.7 (24.1 to 54.6) | 52.3 (35.7 to NA) |
IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, such as left heart failure, pulmonary embolism, pulmonary infection (on the basis of endotracheal aspirate or bronchoalveolar lavage if available, or investigator judgment), or other events leading to acute lung injury (for example, sepsis, aspiration, trauma, reperfusion pulmonary edema).
| percentage of participants | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Percentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation | 3.9 | 3.9 | 6.3 | 2.9 |
Time from randomization to first occurrence of an event of IPF exacerbation was reported. IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, or other events leading to acute lung injury. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| weeks | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Time to First Event of Acute IPF Exacerbation | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| percentage of participants | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|
| Percentage of Participants With Respiratory-Related Hospitalization | 15.4 | 14.5 |
Time from randomization to first occurrence of an event of respiratory-related hospitalization was reported. Participants without an event were censored at the last known alive day, study Day 368, or the last date during the double-blind period. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| weeks | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|
| Time to Respiratory-Related Hospitalization | NA (NA to NA) | NA (NA to NA) |
DLco (in mL/min/mmHg) is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100.
| percentage of participants | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Percentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause | 9.2 | 6.6 | 14.9 | 11.0 |
DLco is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100. Time from randomization to first occurrence of \>/=15% absolute decrease in percentage of predicted DLco or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
| weeks | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Time to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
ATA to lebrikizumab was tested using a validated immunoassay. A positive ATA result was defined as one in which the presence of detectable ATAs could be confirmed by competitive binding with lebrikizumab. Percentage of participants with positive results for ATA at Baseline and at post-baseline time points were reported. Only participants who received lebrikizumab were included in the analysis.
| percentage of participants | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|
| Baseline | 5.3 | 1.8 |
| Post-Baseline | 6.7 | 5.2 |
Participants who received lebrikizumab were only included in the analysis.
| micrograms per milliliter (mcg/mL) | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|
| Minimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 52 | 29.6 ± 14.0 | 25.2 ± 12.7 |
Participants who received lebrikizumab were only included in the analysis.
| mcg/mL | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|
| Cmin at Week 4 | 14.0 ± 4.86 | 14.9 ± 5.75 |
| Cmin at Week 12 | 24.4 ± 9.86 | 25.0 ± 11.0 |
| Cmin at Week 24 | 28.5 ± 12.5 | 25.7 ± 12.4 |
| Cmin at Week 36 | 29.9 ± 14.1 | 25.6 ± 13.8 |
Elimination half-life is the time measured for the plasma drug concentration to decrease by one-half during the elimination phase of the drug. Analysis was performed on PK-Evaluable Population. Participants who received lebrikizumab were only included in the analysis.
| days | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|
| Elimination Half-Life (t1/2) of Lebrikizumab | 23.5 ± 5.36 | 21.9 ± 4.79 |
Collected over Baseline up to Week 122. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy (Cohort A): Placebo | 4/76 (5.3%) | 19/76 (25%) | 70/76 (92.1%) |
| Monotherapy (Cohort A): Lebrikizumab | 4/78 (5.1%) | 23/78 (29.5%) | 73/78 (93.6%) |
| Combination Therapy (Cohort B): Placebo + Pirfenidone | 15/177 (8.5%) | 47/177 (26.6%) | 158/177 (89.3%) |
| Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone | 7/174 (4%) | 56/174 (32.2%) | 142/174 (81.6%) |
| Event | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 13/76 | 11/78 | 22/177 | 17/174 |
| Lower respiratory tract infectionInfections and infestations | 1/76 | 4/78 | 2/177 | 1/174 |
| PneumoniaInfections and infestations | 2/76 | 3/78 | 7/177 | 7/174 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/76 | 2/78 | 1/177 | 2/174 |
| Respiratory tract infectionInfections and infestations | 1/76 | 1/78 | 3/177 | 5/174 |
| Coronary artery diseaseCardiac disorders | 2/76 | 0/78 | 2/177 | 2/174 |
| Pancreatitis acuteGastrointestinal disorders | 2/76 | 0/78 | 0/177 | 0/174 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/76 | 1/78 | 1/177 | 1/174 |
| PneumomediastinumRespiratory, thoracic and mediastinal disorders | 2/76 | 0/78 | 0/177 | 1/174 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/76 | 2/78 | 0/177 | 1/174 |
| Event | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone |
|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 19/76 | 21/78 | 46/177 | 33/174 |
| NasopharyngitisInfections and infestations | 19/76 | 17/78 | 25/177 | 31/174 |
| Upper respiratory tract infectionInfections and infestations | 13/76 | 18/78 | 38/177 | 31/174 |
| DiarrhoeaGastrointestinal disorders | 16/76 | 17/78 | 23/177 | 18/174 |
| FatigueGeneral disorders | 12/76 | 15/78 | 22/177 | 28/174 |
| BronchitisInfections and infestations | 11/76 | 15/78 | 11/177 | 17/174 |
| DizzinessNervous system disorders | 10/76 | 14/78 | 14/177 | 11/174 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/76 | 14/78 | 18/177 | 13/174 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 13/76 | 11/78 | 10/177 | 9/174 |
| NauseaGastrointestinal disorders | 10/76 | 10/78 | 23/177 | 28/174 |
Analysis was performed on Intent-to-Treat (ITT) Population, which included all participants who were randomized in the study, with participants grouped according to the treatment assignment at randomization.
| Age, Customized(participants) | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone | Total |
|---|---|---|---|---|---|
| From 40 to <55 years | 2 | 1 | 6 | 2 | 11 |
| From 55 to <65 years | 18 | 10 | 40 | 41 | 109 |
| From 65 to <75 years | 38 | 44 | 99 | 92 | 273 |
| >/=75 years | 18 | 23 | 32 | 39 | 112 |
| Sex: Female, Male(Participants) | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone | Total |
|---|---|---|---|---|---|
| Female | 13 | 13 | 30 | 37 | 93 |
| Male | 63 | 65 | 147 | 137 | 412 |
| Ethnicity (NIH/OMB)(Participants) | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 13 | 15 | 43 |
| Not Hispanic or Latino | 64 | 68 | 160 | 155 | 447 |
| Unknown or Not Reported | 3 | 4 | 4 | 4 | 15 |
| Race (NIH/OMB)(Participants) | Monotherapy (Cohort A): Placebo | Monotherapy (Cohort A): Lebrikizumab | Combination Therapy (Cohort B): Placebo + Pirfenidone | Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 1 | 3 |
| Asian | 11 | 8 | 19 | 15 | 53 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 0 | 2 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 60 | 66 | 149 | 151 | 426 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 3 | 2 | 7 | 6 | 18 |
Showing the first 100 of 112 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2013 to primary completion in Jul 2017, 45 months.
Results were first posted in Aug 2018, 1 year after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lebrikizumab · Pirfenidone
Idiopathic Pulmonary Fibrosis →